We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Read MoreHide Full Article
Aquestive Therapeutics (AQST - Free Report) shares ended the last trading session 16% higher at $6.09. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 93% gain over the past four weeks.
The sudden surge in the stock price can be attributed to Aquestive's announcement regarding achieving the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to treat severe allergic reactions, including anaphylaxis. The stock price surge was also likely boosted by findings from the FDA Type C meeting. The company expects to file a new drug application for Anaphylm to treat this indication by the end of 2024.
This specialty pharmaceutical company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of -181.8%. Revenues are expected to be $12.47 million, up 12% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aquestive Therapeutics, the consensus EPS estimate for the quarter has been revised 13.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on AQST going forward to see if this recent jump can turn into more strength down the road.
Aquestive Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Collegium Pharmaceutical (COLL - Free Report) , finished the last trading session 2.8% higher at $39.09. COLL has returned 12% over the past month.
Collegium Pharmaceutical's consensus EPS estimate for the upcoming report has changed +11.9% over the past month to $1.50. Compared to the company's year-ago EPS, this represents a change of +13.6%. Collegium Pharmaceutical currently boasts a Zacks Rank of #1 (Strong Buy).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
Aquestive Therapeutics (AQST - Free Report) shares ended the last trading session 16% higher at $6.09. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 93% gain over the past four weeks.
The sudden surge in the stock price can be attributed to Aquestive's announcement regarding achieving the primary and secondary endpoints in the two-part phase III pivotal pharmacokinetic clinical study of Anaphylm (epinephrine) Sublingual Film to treat severe allergic reactions, including anaphylaxis. The stock price surge was also likely boosted by findings from the FDA Type C meeting. The company expects to file a new drug application for Anaphylm to treat this indication by the end of 2024.
This specialty pharmaceutical company is expected to post quarterly loss of $0.09 per share in its upcoming report, which represents a year-over-year change of -181.8%. Revenues are expected to be $12.47 million, up 12% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Aquestive Therapeutics, the consensus EPS estimate for the quarter has been revised 13.3% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on AQST going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Aquestive Therapeutics is a member of the Zacks Medical - Drugs industry. One other stock in the same industry, Collegium Pharmaceutical (COLL - Free Report) , finished the last trading session 2.8% higher at $39.09. COLL has returned 12% over the past month.
Collegium Pharmaceutical's consensus EPS estimate for the upcoming report has changed +11.9% over the past month to $1.50. Compared to the company's year-ago EPS, this represents a change of +13.6%. Collegium Pharmaceutical currently boasts a Zacks Rank of #1 (Strong Buy).